ライフサイエンスコーパス: blood product

1 OLTs, and 79.6% of them did not receive any blood product.

2 te antibodies or bioactive lipids within the blood product.

3 Of these patients, 80.3% did not receive any blood product.

4 failure within hours of the transfusion of a blood product.

5 clotting factor deficiency is infused with a blood product.

6 on-related risks and high rates of discarded blood product.

7 ive variability is the use of intraoperative blood products.

8 rved, and no patient required transfusion of blood products.

9 enitor cells, as well as more-differentiated blood products.

10 re and is prevalent among patients receiving blood products.

11 sponsive voxels or voxels containing chronic blood products.

12 loids received significantly more allogeneic blood products.

13 ecting drug use (IDU) and contaminated blood/blood products.

14 well as their detection and elimination from blood products.

15 others, sexual intercourse, and contaminated blood products.

16 e incidence of TRALI from high plasma volume blood products.

17 ght the importance of developing alternative blood products.

18 the prevention of transmission via blood and blood products.

19 of > or = 500 mL of intravenous fluid and/or blood products.

20 as the use of hemostatic agents and special blood products.

21 s>20/FFP>5) or low (RBCs<20/FFP<5) amount of blood products.

22 carrying capacity (OCC) and coagulation with blood products.

23 hrs of the transfusion of plasma-containing blood products.

24 ed cells were the most frequently transfused blood products.

25 n be performed safely without the use of any blood products.

26 e screening methods to identify WNV-infected blood products.

27 l LDLT in Jehovah's Witness patients without blood products.

28 ous stem-cell support without the use of any blood products.

29 ntly requiring limited amounts of transfused blood products.

30 currently do not include much information on blood products.

31 fections result from transfusion of blood or blood products.

32 ed with the transfusion of plasma-containing blood products.

33 ns, antibiotics, mechanical ventilation, and blood products.

34 g and thereby complicate the safe release of blood products.

35 od but only 7 (7.4%) could separate and bank blood products.

36 pro-oxidant compounds in clinically relevant blood products.

37 a logistical necessity to provide sufficient blood products.

38 uma may be exacerbated by the transfusion of blood products.

39 s, in particular transfusion of contaminated blood products.

40 the use of IV fluids, vasoactive agents, or blood products.

41 mendations supporting the restrictive use of blood products.

42 sible spongiform encephalopathies (TSEs) via blood products.

43 ) of 65 patients and 23 (35%) of 65 received blood products (15 received fresh frozen plasma and eigh

44 pretransplant contributor to charges, while blood products (23%), room and service (21%), organ acqu

45 ensitized groups (P>0.4 for all) in usage of blood products (6411 vs. 6339 units) and time to HTX (28

46 Blood product administration was normalized for the numb

47 inicians are knowledgeable about appropriate blood product administration, as well as the signs, symp

48 mplementation of DCR reduces crystalloid and blood product administration.

49 Exclusion criteria were anticoagulant or blood product administration.

50 sion-acquired viral infections from blood or blood products, adopted diagnostic tests and procedures

51 Culture-independent mNGS of blood products afforded rapid and precise assessment of

52 Culture-independent mNGS of blood products afforded rapid and precise assessment of

53 The system returns the remaining blood products after CTC enrichment, permitting interrog

54 Transfusion of allogeneic blood products, although potentially life-saving, is ass

55 ignificant difference in the requirement for blood products among patients with and without varices.

56 fference in the number of patients receiving blood products among the treatment groups.

57 rimary outcome of interest was first 24-hour blood product and fluid resuscitation requirements.

58 rious arrhythmias, as well as similar use of blood products and 28-day mortality.

59 t complications following the transfusion of blood products and are associated with significant morbi

60 A light (PUVA) are used to kill pathogens in blood products and as a treatment of aberrant cell proli

61 Among them are blood products and blood meal, which are used as high-qu

62 end points included need for transfusion of blood products and chest tube output.

63 h, and initial (24-hour) and total volume of blood products and fluid administered.

64 wn complication following the transfusion of blood products and is commonly referred to as transfusio

65 has declined in developed countries, unsafe blood products and medical practices continue to increas

66 rotocols featuring immediate availability of blood products and multidisciplinary communication reduc

67 incidence, clinical presentation, associated blood products and organisms, and the most feasible and

68 mber and proportion of patients who received blood products and other hemostatic treatments.

69 ers that would allow the detection of bovine blood products and processed animal proteins using tande

70 operation times, intra-aortic balloon pump, blood products and resternotomy.

71 of VAD patients receiving leukocyte-reduced blood products and standardized HLA antibody testing, ro

72 of VAD patients receiving leukocyte-reduced blood products and standardized HLA antibody testing, ro

73 resting" T cells, which can be isolated from blood products and succumb to cART once activated.

74 The blood products and their interaction responsible for SEC

75 tates have included transfusion of blood and blood products and transplantation of solid organs from

76 and human studies suggest that blood donor, blood product, and transfusion recipient variables poten

77 1) of patients with a history of exposure to blood products, and 4% (1 of 25) of patients without par

78 equipment, monitors, medicines, oxygen, and blood products, and an absence of meaningful data to gui

79 infected donors and recipients of blood and blood products, and assessment of TTV's aetiological rol

80 ignificant decline in blood loss, the use of blood products, and hospital stay.

81 h's Witnesses regarding the use of blood and blood products, and how to ensure that those patients pr

82 s, readmission and reoperation rates, use of blood products, and lengths of stay in the intensive car

83 LOS pretransplant, blood products, and operating room services represent po

84 mitigate the risks from TSE-infected blood, blood products, and other materials exposed to TSE infec

85 hil antigen antibodies present in transfused blood products, and predisposing factors such as inflamm

86 agement include hemodialysis, transfusion of blood products, and prohemostatic drugs.

87 ze patients' coagulation, reduce exposure to blood products, and to improve patient outcomes.

88 Bleeding requiring blood product application occurred in three of 10 venove

89 gnosis before live vaccines or nonirradiated blood products are given and before development of infec

90 Although anaphylactic reactions to blood products are rare, the incidence of allergic react

91 Leukoreduced blood products are reportedly comparable to cytomegalovi

92 Babesia spp. and the movement of donors and blood products around the United States has resulted in

93 nd mortality requires rapid delivery of safe blood products as an integral element of advanced trauma

94 optimal care and ensuring judicious usage of blood products, as is keeping abreast of novel therapeut

95 Changing blood product availability and composition will lead to

96 None received antifibrinolytics or blood products before TEG testing.

97 rounding the risk of transmission of vCJD by blood products, blood transfusion services in a number o

98 safer to handle and easier to store than wet blood products, but factors such as intraspot variabilit

99 lion typed volunteer donors and 645,646 cord blood products by 2012.

100 ve patients who had received HTLV-I-infected blood products by transfusion.

101 an immunodeficiency virus (HIV) in blood and blood products can be achieved by a sensitive nucleic ac

102 ation and transfusion, and their presence in blood products can cause lethal transfusion-related acut

103 All blood products can cause TRALI, and no specific treatmen

104 However, aged blood products can cause transfusion-related acute lung

105 They were treated between 1969 and 1985 with blood products carrying a high risk of HCV infection, an

106 e unit admission, intubation, transfusion of blood products, central venous catheter placement, prese

107 The United States has thousands of licensed blood product collection centers that produce millions o

108 rategy leads to a significantly lower use of blood products compared to SOC (transfusion guided by IN

109 Lyophilized and recombinant blood product components may have advantages over tradit

110 immunoglobulin (IVIg), a fractionated human blood product containing polyclonal antibodies, act as i

111 hreat than the combined risks of receiving a blood product contaminated with HIV-1 or 2, hepatitis C

112 r adjustment for age, gender, comorbidities, blood products, crystalloid/12 hrs, presence of any head

113 Disaster logs, patient injuries, and blood product data were prospectively collected during t

114 The use of blood products did not differ between groups (UFH=2.7+/-

115 retrievals and implantation, less organs and blood products donated, limited space in the intensive c

116 atelets were given along with numerous other blood products during posterior spine surgery.

117 Severely malnourished patients require more blood products during surgery and have prolonged postope

118 received transfusions of at least 3 units of blood products during the first 24 hours after admission

119 sfusion of CMV-seronegative and leukoreduced blood products effectively prevents transmission of CMV

120 xclusion criteria were pregnancy, receipt of blood products (except albumin) in the previous 3 months

121 measurements to predict total perioperative blood product exposure and operative mortality.

122 roviding immunomodulatory therapies prior to blood product exposure in select recipients with a histo

123 Each 10-unit increase in total perioperative blood product exposure increased the odds of operative d

124 the UMHS cohort, median total perioperative blood product exposure was 74 units (25th and 75th perce

125 3.8 units (beta+/-SE) of total perioperative blood product exposure.

126 blood donors and patients with FHF, and from blood products (factor VIII and IX clotting-factor conce

127 es, sedative exposures, routes of nutrition, blood products, fluid balance, and modes of ventilatory

128 ght to evaluate the need and availability of blood products for patients with hematological malignanc

129 yed an important role in identifying matched blood products for transfusion.

130 diagnosed and underreported in recipients of blood products from a donor whose blood products may hav

131 measures will be analyzed in urine, DBS, or blood products from the older adult women.

132 dose that inactivates >5 log10 of T cells in blood products, had minimal effect on cytokine synthesis

133 tion on donors and recipients of >20 million blood products handled by the Danish and Swedish blood b

134 ion of lipids accumulated in stored cellular blood products has been made in those cases.

135 ed on donor leukocytes during transfusion of blood products has been shown to impact the recipient's

136 , but the risk for the intraoperative use of blood products has increased.

137 Ehrlichiosis acquired from transfusion of blood products has not been documented in the literature

138 to transfusion of vCJD-contaminated blood or blood products have been described.

139 Platelet rich blood products have been shown to have anti-microbial pr

140 ve lipids that accumulate in older, cellular blood products, have been replicated in animal models.

141 increased mortality among patients receiving blood products (HR 1.65; 95% CI 1.17-2.32, P = 0.004).

142 coagulopathy by proactive resuscitation with blood products in a balanced ratio of RBC:plasma:platele

143 ponents may have advantages over traditional blood products in certain clinical circumstances.

144 efore, maintaining a dependable inventory of blood products in combat support hospitals is essential.

145 ntly been recognized that the transfusion of blood products in critically ill or injured patients inc

146 ssion of variant Creutzfeld-Jakob disease by blood products in humans.

147 veloped management guidelines for the use of blood products in sepsis that would be of practical use

148 reduce bleeding and minimize transfusion of blood products in the setting of clotting factor deficie

149 The utilization of blood products in the treatment of major burn injury sho

150 high rates of transmission through infected blood products, including in medical settings; limited a

151 e risk increases as the number of transfused blood products increase.

152 n the rates of transfusion of RBCs and other blood products, independent of case mix, among patients

153 lop sepsis if they are given high amounts of blood products, indicating an immunocompromised state fo

154 tay > or =15 days, blood usage > or =36 U of blood products, infection, rejection, and global resourc

155 e evidence that the presence of subarachnoid blood products is associated with DNA fragmentation and

156 true incidence of this pulmonary reaction to blood products is currently conjectural at best.

157 iral transmission from contaminated blood or blood products is extremely rare, and in developing coun

158 rare, the incidence of allergic reactions to blood products is similar to the allergic reaction incid

159 it remains controversial whether infusion of blood products is superior to crystalloids alone.

160 Because bacterial contamination of blood products is the most frequent cause of transfusion

161 associated with the administration of equine blood products; its etiologic agent has remained unknown

162 Other outcomes included transfusion of other blood products, major bleeding, and major complications.

163 than the level of infectivity present in the blood product make a significant contribution to underst

164 Discuss the pros and cons of using donor and blood product-management strategies to prevent transfusi

165 tients developing sepsis from a contaminated blood product may meet the clinical definition of transf

166 Transfusion of "older" blood products may contribute to a higher risk of postop

167 ipients of blood products from a donor whose blood products may have caused TRALI in several transfus

168 ia who received influenza-convalescent human blood products may have experienced a clinically importa

169 dition to more strict criteria of the use of blood products, may improve outcome after TAVI.

170 e residual level of cytomegalovirus (CMV) in blood products measured by quantitative polymerase chain

171 acquired HIV through transfusion of blood or blood products (median age at cancer diagnosis, 13.4 yea

172 Only intraoperative use of blood products, not operative case length, hypotension,

173 and obviates the necessity of using limited blood products obtained from a small number of HPS survi

174 njecting his former girlfriend with blood or blood-products obtained from an HIV type 1 (HIV-1)-infec

175 dicted body weight, p <.001), transfusion of blood products (odds ratio, 3.0; p < 0.001), acidemia (p

176 1.16-58, p = 0.04); maternal transfusion of blood products, odds ratio 7.24 (95% confidence interval

177 involving the thoracic aorta; transfusion of blood products of > or =10 units; and cardiopulmonary by

178 gastrointestinal hemorrhage who refused all blood products on religious grounds.

179 er may limit the toxic effects of persistent blood products on surrounding tissue and may be importan

180 ed to plan for high use of advanced imaging, blood products, operating room availability, nursing res

181 received transplants before HCV screening of blood products or donors, 10.2% developed de novo HCV di

182 approaches, such as the use of concentrated blood products or osteoprogenitor cells in conjunction w

183 n donor, and remove any potentially infected blood products or tissues.

184 ported travel to other countries, receipt of blood products, or drug injection.

185 ed by Ixodes ticks, transfusion of blood and blood products, organ donation, and perinatally.

186 posing risk to others via blood transfusion, blood products, organ or tissue grafts, and contaminated

187 operatively, patients with PGD received more blood products (P < 0.001).

188 rative bleeding as evidenced by the units of blood products (packed red blood cells or platelets) tra

189 The following blood products produced faint VD values: washed red bloo

190 ed to a lack of availability of this primary blood product, providing a strong rationale for developi

191 Earlier transfusion with higher blood product ratios (plasma, platelets, and red blood c

192 dings represent the largest study evaluating blood product ratios in pediatric trauma patients, prosp

193 Blood product ratios of 1:1:1 (338 patients) vs 1:1:2 (3

194 udies are necessary to determine the optimum blood product ratios to minimize mortality in this popul

195 cumentation and four required transfusion of blood products (RBCs, n = 2; platelet, n = 2).

196 Women progressing to 8 U blood products (red blood cells [RBCs] + fresh frozen pl

197 s study was to determine whether prehospital blood products reduce 30-day mortality in patients at ri

198 transfusion of influenza-convalescent human blood products reduced mortality in patients with influe

199 bumin), bilirubin levels, and intraoperative blood product requirements could be statistically linked

200 tibodies, as well as alternate substances in blood products, result in neutrophil activation, which,

201 actions and limit availability of compatible blood products, resulting in anemia-associated morbidity

202 Chronic blood product shortages, as well as the known and unknow

203 If massive transfusion is anticipated, blood products should be administered from the outset to

204 The risk and benefits of all blood products should be assessed before transfusion.

205 risks of transfusion-related adverse events, blood products should be used judiciously.

206 BEST PRACTICE ADVICE 3: Blood products should be used sparingly because they inc

207 Transfusion of blood products should not be withheld from surgical pati

208 es, as well as the known and unknown risk of blood products, should serve as the driving force for de

209 Leukocyte reduction of donated blood products substantially reduces the risk of a numbe

210 rs, and the extent to which TTV contaminates blood products such as factor VIII and IX clotting facto

211 Maintaining a robust blood product supply is an essential requirement to guar

212 ow-up, all 6 surviving patients were free of blood product support and thrombopoietic agonists.

213 confirmation of the diagnosis and aggressive blood product support are critical to reduce early morta

214 tients randomly assigned to CC required more blood product support.

215 o perform autologous transplantation without blood-product support.

216 The total number of units of blood products that were transfused during hospitalizati

217 roportionately large quantities of blood and blood products, the immunomodulatory effects of blood tr

218 ation, particularly in terms of the ratio of blood products to each other and the timing of these pro

219 erstand the composition of the available new blood products to use them correctly.

220 Platelets are a frequently requested blood product today and are often in limited supply beca

221 hospital-acquired aspiration, and volume of blood products transfused and fluids administered.

222 which helps to reduce the number of units of blood products transfused in the actively bleeding patie

223 ence of EEEV infection among donors of the 8 blood products transfused into the organ donor or in pro

224 ator-free days, renal failure-free days, and blood products transfused) and compliance with each guid

225 gic and thrombotic events, and the amount of blood products transfused.

226 4%; P=0.96) or requirement for postoperative blood product transfusion (adjusted OR, 1.17; 95% CI, 0.

227 tality (odds ratio, 0.40; P=0.017), need for blood product transfusion (odds ratio, 0.74; P=0.009), m

228 s is likely related to the administration of blood product transfusion after the onset of fulminant h

229 ndrome continues to be supportive care, with blood product transfusion and antibiotics for infectious

230 nal shock, maternal requirement of allogenic blood product transfusion and lower gestational age were

231 to intervention, total procedural duration, blood product transfusion and salvages a small subset of

232 et count), and its use may avoid unnecessary blood product transfusion in patients with cirrhosis and

233 Timely LDLT can be done successfully without blood product transfusion in selected patients.

234 Red blood cell and blood product transfusion in the fetus, neonate, and pre

235 Prehospital blood product transfusion in trauma care remains controv

236 Restrictive blood product transfusion practices following congenital

237 military combat causalities in Afghanistan, blood product transfusion prehospital or within minutes

238 n the incidence of hemostatic reexploration, blood product transfusion rates, morbidity, and mortalit

239 ntly, Jehovah's Witness patients, who refuse blood product transfusion, are usually excluded from liv

240 risk of reoperation for bleeding or need for blood product transfusion.

241 tients (69%), and 28 patients (67%) required blood product transfusion.

242 and related physician orders, demographics, blood products transfusion, and outcomes were collected

243 ump CABG, significantly reduced the rates of blood-product transfusion (50.7% vs. 63.3%; relative ris

244 Early postoperative chest-tube output, blood-product transfusion requirements, and levels of se

245 Pugh B: 26; C: 58) without overt bleeding or blood-product transfusion were prospectively evaluated w

246 2% vs. 2.4%, p = 0.002), had higher rates of blood product transfusions (13.1% vs. 3.1%, p < 0.0001),

247 irus infection that presumably resulted from blood product transfusions administered before the intro

248 seropositive, and who received more than 20 blood product transfusions before BMT.

249 ostatic reoperation and the requirements for blood product transfusions during and after off-pump cor

250 to treat, 22.6), but had no effect on other blood product transfusions or major complications.

251 ocol, all subjects in the SOC group received blood product transfusions versus 5 in the TEG group (10

252 m amplitude were also less likely to receive blood product transfusions within 24 hours of testing co

253 Bleeding, blood product transfusions, and thrombosis were not diff

254 rs such as total parenteral nutrition (TPN), blood product transfusions, invasive procedures, central

255 nt has reduced intraoperative blood loss and blood product transfusions.

256 iated with major blood loss and the need for blood product transfusions.

257 ed growth factor support, and three required blood product transfusions.

258 , continuous veno-venous hemofiltration, and blood product transfusions.

259 ause of Jehovah's Witnesses' (JW) refusal of blood products, treatment challenges arise.

260 loid infusion volume and number of the total blood product units given in the first 24 hours decrease

261 102 359 632 (95% UI 93 381 710-111 360 725) blood product units, equal to 1849 (1687-2011) units per

262 ly was 272 270 243 (268 002 639-276 698 494) blood product units, with a need-to-supply ratio of 1.12

263 r patient morphometry, crystalloid, colloid, blood products, urine, blood loss, duration, and approac

264 strates improved mortality and lower overall blood product usage with higher ratios of plasma and pla

265 associated with a short anhepatic phase, low blood product usage, and short intensive care unit stay.

266 egard to duration of surgery, intraoperative blood product usage, liver and renal function, volume of

267 ch is associated with a reduction in overall blood product use and a 60% decreased odds in 30-day mor

268 Endpoints were blood product use and bleeding complications.

269 inued use of aprotinin, but rather increased blood product use has occurred with the attendant costs

270 mographic variables, diagnosis category, and blood product use history (in patients with blood group

271 However, daily blood product use is difficult to anticipate.

272 els that triggered a transfusion and overall blood product use were obtained for patients undergoing

273 , surgeon, warm and cold ischemic times, and blood product use were recorded.

274 Demographics, blood product use, primary diagnosis, cold ischemic time

275 The incidences of blood-product use, infection, and serious adverse events

276 ment of hemorrhage, including transfusion of blood products, use of hemostatic bandages/agents, and t

277 rts to support order auditing, assessment of blood product utilization and compliance monitoring.

278 that early postoperative adverse events and blood product utilization would affected in this post-ap

279 r-associated bloodstream infections, reduces blood product utilization, and improves communication du

280 ith dosage modification, or growth factor or blood product utilization.

281 A restrictive transfusion strategy halved blood product utilization.

282 enomes in living cells, the sterilization of blood products, vaccine development, and viral inactivat

283 illary outcomes included time to hemostasis, blood product volumes transfused, complications, inciden

284 In the past, transfusion of blood and blood products was an important source of HCV transmissi

285 ients tested, a history of prior exposure to blood products was associated with an increased risk of

286 ion models confirmed that the transfusion of blood products was independently associated with altered

287 The use of therapeutic blood products was significantly associated with the pre

288 fected by the increasing use of leukoreduced blood products, we followed a prospective cohort of 807

289 , when only CMV-seronegative and/or filtered blood products were provided, and period 2 (12/96-2/00),

290 Blood products were transfused in 72 (64%) patients with

291 ations were performed and 117 total units of blood products were transfused.

292 17 patients needed surgery and 264 units of blood products were used in the first 15 h, close to the

293 No blood products were used in transfusion-free patients wh

294 hemorrhagic shock should receive prehospital blood products when available, preferably packed red blo

295 hemorrhagic shock should receive prehospital blood products when available, preferably PRBC+plasma.

296 nown in several insects to contribute to the blood products which are endocytosed along with vitellog

297 ne priming step followed by transfusion of a blood product with either leukocyte allo-antibodies or b

298 ated 26 patients with religious objection to blood products with autologous stem-cell support without

299 rum, in patients receiving leukocyte-reduced blood products, with standardized HLA antibody detection

300 ly represent venous engorgement and/or acute blood products within the spinal cord.